ClinicalTrials.gg
Not yet recruitingNCT07656493LAMB-SOTUpdated Jun 24, 2026

Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients

An observational study in Invasive Fungal Infection, Solid Organ Transplantation and Opportunistic Infections, sponsored by Sichuan Provincial People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Sichuan Provincial People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Invasive Fungal Infections with a site in China — 12 open to participants now, 12 under way, none of them phase 3. Invasive Fungal Infections · China.

Planned enrollment
8th of 17
120 · median 120
Started
2026
with 3 others
Observational
17 of 29
10 open now
Primary completion
2028-03
later than 9 of 11 live
Registered
25th of 29
by date
Lead sponsor
2 of 29
Sichuan Provincial People's Hospital

Among the 29 studies in Invasive Fungal Infections with a site in China, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2026, is one of 17 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 25th registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

12 of the 29 studies in Invasive Fungal Infections with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Invasive Fungal Infections with a site in China, or all of them as a file.
02

Study summary

This real-world observational study aims to evaluate the effectiveness, safety, and therapeutic drug monitoring (TDM) of liposomal amphotericin B (L-AmB) in solid organ transplant recipients with invasive fungal disease (IFD). IFD is a major cause of morbidity and mortality in transplant recipients because of long-term immunosuppressive therapy and increased susceptibility to opportunistic fungal infections.

This is a single-center ambispective cohort study conducted at Sichuan Provincial People's Hospital. The study includes a prospective cohort of solid organ transplant recipients receiving L-AmB therapy and a historical control cohort treated with alternative systemic antifungal regimens. Clinical management and treatment decisions will be determined by treating physicians according to routine clinical practice, and no study-specific intervention will be introduced.

The study will collect information on demographic characteristics, transplant type, immunosuppressive regimens, fungal pathogens, infection sites, antifungal treatment strategies, laboratory findings, and clinical outcomes. Particular attention will be given to renal safety, electrolyte abnormalities, and therapeutic drug monitoring of liposomal amphotericin B. Plasma concentrations of L-AmB, treatment modifications, temporary treatment discontinuation, and concentration-related safety and effectiveness outcomes will be recorded during antifungal therapy.

The primary outcomes are the 28-day clinical response rate and 84-day all-cause mortality. Secondary outcomes include mycological clearance, acute kidney injury, electrolyte abnormalities, breakthrough fungal infection, treatment discontinuation due to adverse events, liposomal amphotericin B plasma concentrations, and the associations between L-AmB exposure and clinical outcomes or treatment-related toxicities.

The study is expected to provide real-world evidence regarding the effectiveness, safety, and pharmacokinetic characteristics of L-AmB in transplant recipients, support optimization of antifungal treatment strategies, and inform individualized dosing and monitoring approaches in this high-risk population.

03

Conditions studied

  • Invasive Fungal Infection
  • Solid Organ Transplantation
  • Opportunistic Infections

Keywords

  • Liposomal Amphotericin B
  • Solid Organ Transplantation
  • Invasive Fungal Disease
  • Antifungal Therapy
  • Tacrolimus
  • Cyclosporine
  • Therapeutic Drug Monitoring
  • Drug-Drug Interaction
  • Real-World Study
  • Transplant Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult solid organ transplant recipients diagnosed with proven, probable, or possible invasive fungal disease and treated with liposomal amphotericin B or alternative systemic antifungal therapy at Sichuan Provincial People's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years.
  • Recipient of a solid organ transplant.
  • Diagnosis of invasive fungal disease (IFD) according to EORTC/MSGERC criteria.
  • Receiving liposomal amphotericin B therapy as part of routine clinical care.
  • Provision of for prospective participants.

Exclusion criteria

Exclusion Criteria:

  • Known to amphotericin B formulations.
  • Severe hepatic dysfunction ( or AST >5× , or total >2× upper limit of normal).
  • Severe renal dysfunction requiring permanent discontinuation of antifungal therapy at baseline.
  • Pregnancy or breastfeeding.
  • Participation judged inappropriate by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Liposomal Amphotericin B Cohort

    Solid organ transplant recipients with invasive fungal disease receiving liposomal amphotericin B therapy.

    Drug: Liposomal Amphotericin B

  • Historical Control Cohort

    Historical control patients with invasive fungal disease treated with alternative systemic antifungal regimens.

    Drug: Alternative Systemic Antifungal Therapy

Interventions

  • Liposomal amphotericin B administered for treatment of proven, probable, or possible invasive fungal disease in solid organ transplant recipients according to routine clinical practice. Dose adjustment and treatment duration are determined by treating physicians.

    Also known as: L-AmB

  • DrugAlternative Systemic Antifungal Therapy

    Alternative systemic antifungal agents including azoles, echinocandins, or other standard antifungal therapies administered according to routine clinical practice in historical control patients with invasive fungal disease.

    Also known as: Azoles, Echinocandins

06

What researchers measure

Primary outcomes

  1. 28-Day Clinical Response Rate

    Proportion of participants achieving complete or partial clinical response at Day 28 after initiation of antifungal therapy.

    Time frame: Day 28

  2. 84-Day All-Cause Mortality

    All-cause mortality occurring within 84 days after initiation of antifungal therapy.

    Time frame: Day 84

Secondary outcomes

  1. Mycological Clearance Rate

    Proportion of participants with documented clearance of fungal pathogens.

    Time frame: Day 28

  2. Acute Kidney Injury

    Occurrence of acute kidney injury during antifungal treatment.

    Time frame: Baseline through Day 84

  3. Electrolyte Abnormalities

    Occurrence of hypokalemia, hypomagnesemia, or other treatment-related electrolyte disturbances.

    Time frame: Baseline through Day 84

  4. Liposomal Amphotericin B Plasma Concentration

    Plasma concentration of liposomal amphotericin B measured during antifungal therapy.

    Time frame: Baseline through Day 84

  5. Association Between Liposomal Amphotericin B Exposure and Clinical Response

    Relationship between liposomal amphotericin B plasma concentration and clinical response.

    Time frame: Baseline through Day 84

  6. Association Between Liposomal Amphotericin B Exposure and Adverse Events

    Relationship between liposomal amphotericin B plasma concentration and treatment-related adverse events, including nephrotoxicity and electrolyte abnormalities.

    Time frame: Baseline through Day 84

  7. Breakthrough Fungal Infection

    Occurrence of breakthrough invasive fungal infection during antifungal therapy.

    Time frame: Baseline through Day 84

  8. Antifungal Treatment Discontinuation Due to Adverse Events

    Permanent discontinuation of antifungal therapy because of treatment-related adverse events.

    Time frame: Baseline through Day 84

07

Study locations

1 site
08

References and documents

Publications

  • Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008. PubMed 31802125 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to patient confidentiality and institutional data protection requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Mar 2028, 20 months later.

Of 30 observational studies under Invasive Fungal Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 18, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656493
Lead sponsor
Sichuan Provincial People's Hospital
Collaborators
Beijing Science and Technology Innovation Medical Development Foundation
Responsible party
Lingai Pan (Director, Organ Donation Program, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 24, 2026

Study contacts

Lingai Pan, MD
Contact
panlingai2004@163.com
+86 17708130236
Lingai Pan, MD
principal investigator · Sichuan Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion